long term comparing IV vs subcutaneous trastuzumab

[Nguyen]

Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients’ With HER2-Positive Metastatic Breast Cancer


https://www.clinical-breast-cancer.com/article/S1526-8209(23)00164-7/fulltext